Evidence map›Paper›PMID 26415713›Full record

ArticleScientific reports2015

Implementation of an antenatal magnesium sulfate protocol for fetal neuroprotection in preterm infants.

Pierre-Emmanuel Bouet, Stéphanie Brun, Hugo Madar, Anne-Laure Baisson, Véronique Courtay, Géraldine Gascoin-Lachambre, Sigismond Lasocki, Loïc Sentilhes

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Antenatal Magnesium Sulfate and adverse gastrointestinal outcomes in Preterm infants-a systematic review and meta-analysis.Journal of perinatology : official journal of the California Perinatal Association · 2023
    Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Pierre-Emmanuel BouetDepartment of Obstetrics and Gynecology, Montreal University Hospital-Montreal-Canada.
Stéphanie BrunDepartment of Obstetrics and Gynecology, Bordeaux University Hospital-Bordeaux-France.
Hugo MadarDepartment of Obstetrics and Gynecology, Bordeaux University Hospital-Bordeaux-France.
Anne-Laure BaissonDepartment of Obstetrics and Gynecology, Angers University Hospital-Angers-France.
Véronique CourtayDepartment of Obstetrics and Gynecology, Angers University Hospital-Angers-France.
Géraldine Gascoin-LachambreDepartment of Neonatal Medicine, Angers University Hospital-Angers-France.
Sigismond LasockiDepartment of Anesthesiology, Angers University Hospital-Angers-France.
Loïc SentilhesDepartment of Obstetrics and Gynecology, Bordeaux University Hospital-Bordeaux-France.
Université d'Angers · FRUniversité de Bordeaux · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of our study was to assess the feasibility of implementing a protocol for the use of magnesium sulfate to prevent cerebral palsy. This retrospective single-center study included all women with fetuses of gestational age <33 weeks of gestation whose birth was planned or expected within 24 hours from September 2011 to December 2012. They were to receive magnesium sulfate, administered intravenously as a 4-g bolus followed by a constant infusion of 1 g per hour. If delivery had not occurred after 12 hours and was no longer considered imminent, the infusion was to be discontinued. The study included 119 women, 81 (68.1%) of whom received magnesium sulfate. Among the latter, 71 (87.5%) gave birth within 24 hours. The reasons treatment was not given were: omission by medical team (19/38, 50%), urgent delivery (18/38, 47.4%), and contraindication to treatment (1/38, 2.6%). The mean gestational age at protocol implementation was 29.6 +/- 2.1 weeks. Maternal monitoring, especially at the onset of infusion, appeared suboptimal. No major maternal side effects were observed. Our study shows that implementing a protocol for prevention of cerebral palsy by magnesium sulfate is feasible in a tertiary obstetric center.

Indexed as

Infant, PrematureAdultCerebral PalsyDrug Administration ScheduleFemaleGestational AgeHumansInfant, NewbornMagnesium SulfateMonitoring, PhysiologicNeuroprotective AgentsObstetric Labor, PrematurePregnancyRetrospective StudiesTertiary Care CentersMagnesium SulfateNeuroprotective Agents

Identifiers

PMID26415713
PMCPMC4586759
OpenAlexW2415859673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.